We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+6.4%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$189M
AUM Growth
+$9.21M
Cap. Flow
-$665K
Cap. Flow %
-0.35%
Top 10 Hldgs %
92.04%
Holding
44
New
3
Increased
9
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$980K
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$489K
3
XLRN
Acceleron Pharma
XLRN
+$435K
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$420K
5
CORT icon
Corcept Therapeutics
CORT
+$380K

Top Sells

Rank Stock Value
1
VRML
Vermillion, Inc.
VRML
+$859K
2
WKHS icon
Workhorse Group
WKHS
+$655K
3
MASI
Masimo
MASI
+$643K
4
TSRO
TESARO, Inc.
TSRO
+$550K
5
CTRA
Coterra Energy
CTRA
+$502K

Sector Composition

Rank Sector Weight
1 Healthcare 96.5%
2 Energy 2.18%
3 Consumer Staples 0.56%
4 Industrials 0.27%
5 Consumer Discretionary 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PXD
26
DELISTED
Pioneer Natural Resource Co.
PXD
$479K 0.25%
3,000
– –
XLRN
27
DELISTED
Acceleron Pharma
XLRN
$456K 0.24%
+15,000
New +$435K
CELGZ
28
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$360K 0.19%
291,877
– –
BIIB icon
29
Biogen
BIIB
$29.5B
$271K 0.14%
1,000
– –
XNCR icon
30
Xencor
XNCR
$1.39B
$260K 0.14%
12,300
– –
ADXS
31
DELISTED
Advaxis Inc
ADXS
$231K 0.12%
2,373
– –
GNCA
32
DELISTED
Genocea Biosciences, Inc.
GNCA
$204K 0.11%
4,875
– –
WKHS icon
33
Workhorse Group
WKHS
$30.1M
$185K 0.1%
17
-70
-80% -$655K
GNMX
34
DELISTED
Aevi Genomic Medicine Inc
GNMX
$170K 0.09%
128,000
+60,000
+88% +$86.7K
OPK icon
35
Opko Health
OPK
$906M
$159K 0.08%
24,158
– –
ROKA
36
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$121K 0.06%
46,731
– –
PACB icon
37
Pacific Biosciences
PACB
$422M
$96K 0.05%
27,000
– –
OMED
38
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$96K 0.05%
28,689
-6,000
-17% -$24.9K
DRNA
39
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$63K 0.03%
+20,000
New +$63.2K
MACK
40
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$55K 0.03%
5,592
– –
ARAY icon
41
Accuray
ARAY
$29.8M
– –
-40,300
Closed -$191K
CTRA
42
DELISTED
Coterra Energy
CTRA
– –
-21,000
Closed -$502K
ALDR
43
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-15,150
Closed -$315K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Birchview Capital held 44 positions worth $189M, up 5.1% from $180M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q2 2017 filing shows 3 new, 9 increased, 7 reduced and 3 closed positions. Its largest new stake was Acceleron Pharma: 15,000 shares worth $456K. The largest sale was Vermillion, Inc., an estimated $859K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2017 buy was Acceleron Pharma: 15,000 shares worth $456K.
  • Birchview Capital added most to Celgene Corp in Q2 2017, an estimated $980K increase.
  • Birchview Capital's biggest Q2 2017 reduction was Vermillion, Inc., cutting an estimated $859K.
  • Birchview Capital fully exited Coterra Energy in Q2 2017, selling an estimated $502K.
  • Birchview Capital's ten largest holdings make up 92% of its $189M portfolio in Q2 2017.
  • Birchview Capital opened 3 new positions and closed 3 in Q2 2017.
  • Birchview Capital's portfolio value rose 5.1% quarter-over-quarter to $189M.

Based on Birchview Capital's 13F filing for Q2 2017, filed 8 Aug 2017.